- Home
- IKT
as 11-22-2024 4:00pm EST
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ATLANTA |
| Market Cap: | 159.2M | IPO Year: | 2020 |
| Target Price: | $6.50 | AVG Volume (30 days): | 310.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $3.82 | Next Earning Date: | 11-14-2024 |
| Revenue: | $1 | Revenue Growth: | -100.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Inhibikase Therapeutics Inc. (IKT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Munshi Amit | IKT | Director | Oct 21 '24 | Buy | $1.37 | 365,000 | $500,050.00 | 365,000 | |
| Bellini Roberto | IKT | Director | Oct 21 '24 | Buy | $1.37 | 1,460,000 | $2,000,200.00 | 1,460,000 | |
| Kush Arvind | IKT | Director | Oct 21 '24 | Buy | $1.37 | 145,000 | $198,650.00 | 145,000 |
Latest Inhibikase Therapeutics Inc. News
IKT Breaking Stock News: Dive into IKT Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
TipRanks
a month ago
Inhibikase Therapeutics Secures Funding and Strengthens Leadership
GuruFocus.com
a month ago
Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc
GlobeNewswire
a month ago
Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension
GuruFocus.com
a month ago
Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc
TipRanks
a month ago
Inhibikase Therapeutics Secures $110M for Drug Development
GuruFocus.com
a month ago
Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics Shares
TipRanks
a month ago
Inhibikase Therapeutics Unveils PAH and Parkinson’s Drug Pipeline
Compare IKT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IKT Inhibikase Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.